StudyFinder
MT2021-01: PTCy + Sirolimus/VIC-1911 as GVHD prophylaxis in myeloablative PBSC transplantation
Recruiting
The primary objective of this study is to determine the optimal dose of VIC-1911 when given in combination with standard immunosuppressive therapy in adult patients undergoing myeloablative stem cell transplantation.
Clinics and Surgery Center (CSC)
Janine Delage - jdelage@umn.edu
Punita Grover
STUDY00015049
35442
See this study on ClinicalTrials.gov